# Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

> **NCT05840835** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Immix Biopharma, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IMX-110 combined with Tislelizumab

## Key facts

- **NCT ID:** NCT05840835
- **Lead sponsor:** Immix Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-03
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840835, "Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05840835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*